Metvixia

(Methyl Aminolevulinate)

Phase 3Small molecule

GGalderma R&D

Metvixia is one of 59 small molecule programs targeting Basal Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Basal Cell CarcinomaActive, not recruiting

Actinic KeratosisActive, not recruiting

Basal Cell CarcinomaPhase 3

Active, not recruiting

Actinic KeratosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

95 competitors in Actinic Keratosis

#DrugCompanyPhaseTrials

Voltaren

CCerimon Pharmaceuticals

Phase 3

3 2

Treatment

GSK

Phase 3

1 3

Ingenol Metabute

LEO Pharma

Phase 3

18 4

Levulan

BBiomed Industries, Inc.

Phase 2

2 5

Generic Ingenol Mebutate

AActavis Inc.

Phase 3

3 6

Accutane

CConrado Roberto Hoffmann Filho

Phase 2

1 7

Lanoxin

AAdvanz Pharma

Phase 2

1 8

Kenalog

BBassett Healthcare

Phase 2

1 9

Ornidyl

UUSWM, LLC (dba US WorldMeds)

Phase 2

1 10

Metvixia

GGalderma R&D

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Actinic Keratosis1 trial

Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization

Unknown status·UUniversity of Sao Paulo General Hospital·N/A·NCT03013647·20 enrolled

Basal Cell Carcinoma1 trial

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

Completed·BBiofrontera Bioscience GmbH·Phase 3·NCT02144077·281 enrolled

Trial1 trial

Trial of Methyl Aminolevulinate Plus Aktilite in Facial Photodamage

Completed·UUniversidad de Antioquia·Phase 3·NCT00629317·49 enrolled

Efficacy1 trial

Efficacy of Methyl Aminolevulinate + Daylight in Patients With Facial Photodamage

Completed·FFundación Dermabase·Phase 2·NCT02139618·60 enrolled

Regulatory

FDA Approval Timeline[4]

Jul 27, 2004

METVIXIA

NDA NDA021415

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Methyl Aminolevulinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methyl Aminolevulinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methyl Aminolevulinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021415). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Galderma R&D company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGalderma R&D

Metvixia

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Actinic Keratosis1 trial

Basal Cell Carcinoma1 trial

Trial1 trial

Efficacy1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News